Evidence map›Paper›PMID 22414309›Full record

ArticleExperimental neurology2012

Salmon fibrin treatment of spinal cord injury promotes functional recovery and density of serotonergic innervation.

Kelli G Sharp, Amanda R Dickson, Steve A Marchenko, Kelly M Yee, Pauline N Emery, Ivo Laidmåe, Raivo Uibo, Evelyn S Sawyer, Oswald Steward, Lisa A Flanagan

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. 3D Bioprinting for Spinal Cord Injury Repair.Frontiers in bioengineering and biotechnology · 2022
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kelli G SharpReeve-Irvine Research Center and Department of Anatomy & Neurobiology, University of California Irvine, Irvine, CA 92697-1705, USA.
Amanda R Dickson
Steve A Marchenko
Kelly M Yee
Pauline N Emery
Ivo Laidmåe
Raivo Uibo
Evelyn S Sawyer
Oswald Steward
Lisa A Flanagan
University of California, Irvine · USFreeport-McMoRan (United States) · US

Funding

Towards a therapy to regenerate corticospinal axonsR01NS073857 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI STEWARD, OSWALD · 2011 to 2015
$1.7M
Salmon fibrin gels for surgical applicationsR44NS048734 · NINDS · SEA RUN HOLDINGS, INC. · PI SAWYER, EVELYN · 2006 to 2007
$755k
Regulation of neural stem cells by Lhx2K01AG023583 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI FLANAGAN, LISA A · 2004 to 2008
$610k
NIA NIH HHS AG23583NIA NIH HHS K01 AG023583NINDS NIH HHS R01 NS073857NINDS NIH HHS R44 NS048734NINDS NIH HHS R44-NS048734
6 · The paper itself

Abstract

The neural degeneration caused by spinal cord injury leaves a cavity at the injury site that greatly inhibits repair. One approach to promoting repair is to fill the cavity with a scaffold to limit further damage and encourage regrowth. Injectable materials are advantageous scaffolds because they can be placed as a liquid in the lesion site then form a solid in vivo that precisely matches the contours of the lesion. Fibrin is one type of injectable scaffold, but risk of infection from blood borne pathogens has limited its use. We investigated the potential utility of salmon fibrin as an injectable scaffold to treat spinal cord injury since it lacks mammalian infectious agents and encourages greater neuronal extension in vitro than mammalian fibrin or Matrigel®, another injectable material. Female rats received a T9 dorsal hemisection injury and were treated with either salmon or human fibrin at the time of injury while a third group served as untreated controls. Locomotor function was assessed using the BBB scale, bladder function was analyzed by measuring residual urine, and sensory responses were tested by mechanical stimulation (von Frey hairs). Histological analyses quantified the glial scar, lesion volume, and serotonergic fiber density. Rats that received salmon fibrin exhibited significantly improved recovery of both locomotor and bladder function and a greater density of serotonergic innervation caudal to the lesion site without exacerbation of pain. Rats treated with salmon fibrin also exhibited less autophagia than those treated with human fibrin, potentially pointing to amelioration of sensory dysfunction. Glial scar formation and lesion size did not differ significantly among groups. The pattern and timing of salmon fibrin's effects suggest that it acts on neuronal populations but not by stimulating long tract regeneration. Salmon fibrin clearly has properties distinct from those of mammalian fibrin and is a beneficial injectable scaffold for treatment of spinal cord injury.

Indexed as

AnimalsAxonsFemaleFibrinMotor ActivityNerve RegenerationRatsRats, Sprague-DawleyRecovery of FunctionSerotonergic NeuronsSpinal CordSpinal Cord InjuriesTissue ScaffoldsFibrin

Identifiers

PMID22414309
PMCPMC3437931
OpenAlexW2084056352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.